In March 2024, the FDA approved Wegovy for cardiovascular event reduction in adults with obesity and established CVD — the first weight-management drug ever approved for a cardiovascular outcome. The basis was SELECT, the largest cardiovascular outcome trial of a GLP-1 receptor agonist in adults without diabetes.
The SELECT trial
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) enrolled 17,604 adults with BMI ≥27 kg/m² and established cardiovascular disease, without diabetes. They received semaglutide 2.4 mg weekly or placebo, on top of standard CV care.
| Endpoint | Semaglutide | Placebo | Effect |
|---|---|---|---|
| MACE (3-point composite) | 6.5% | 8.0% | 20% relative risk reduction (HR 0.80, p<0.001) |
| CV death | 2.5% | 3.0% | HR 0.85 |
| Non-fatal MI | 2.7% | 3.7% | HR 0.72 |
| Non-fatal stroke | 1.7% | 1.9% | HR 0.93 |
| Weight (104 weeks) | −9.4% | −0.9% | −8.5% difference |
Median follow-up was 39.8 months. The MACE benefit emerged early (within 6 months) and persisted. Weight effect was modestly smaller than in STEP-1, consistent with the older, sicker SELECT cohort.
How SELECT changed clinical practice
- The FDA label for Wegovy now includes CV event reduction in adults with BMI ≥27 and established CVD.
- Since March 2024, Medicare Part D plans may cover Wegovy for its cardiovascular indication. Separately, the Medicare GLP-1 Bridge ($50 copay, July 1, 2026 to December 31, 2027) covers Foundayo, Wegovy and the Zepbound KwikPen for eligible Part D enrollees; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.
- Many commercial plans have added Wegovy to formulary under prior authorization criteria mirroring SELECT enrollment.
What "established CVD" means here
SELECT enrolled patients with any of the following: prior myocardial infarction, prior ischemic or hemorrhagic stroke, or symptomatic peripheral arterial disease. Patients with diabetes were excluded (a separate pathway exists for T2D + CVD via SUSTAIN-6).
Mechanism beyond weight loss
The CV benefit in SELECT outpaces what would be expected from weight loss alone in similar trials. Proposed mechanisms include direct GLP-1 receptor effects in vascular endothelium and myocardium, reduced systemic inflammation, improved insulin sensitivity, and blood pressure reduction. The clinical implication is that the CV benefit is not solely a "lose weight, lower CV risk" story — there is direct pharmacologic benefit.
What we don't yet know
- Primary prevention in obesity without established CVD: Not studied in SELECT. The 2026 STEP-HFpEF, STEP-Kidney, and similar trials extend the benefit profile but do not address primary CV prevention in lower-risk adults with obesity.
- Tirzepatide CV outcomes: In SURPASS-CVOT, tirzepatide was non-inferior to dulaglutide on major cardiovascular events; the Mounjaro label (revised August 2026) now includes a cardiovascular indication for adults with type 2 diabetes. Zepbound has no cardiovascular indication.
- Long-term effects beyond 5 years: No GLP-1 CV outcome trial has yet extended past 5-year follow-up in obesity populations without diabetes.
Clinical takeaways
- For adults with obesity and established CVD, semaglutide 2.4 mg is now a guideline-aligned CV risk-reduction therapy.
- The MACE benefit appears within months and is sustained.
- Coverage barriers are easing. Discuss with the prescriber whether Wegovy through insurance is now accessible.
- Compounded semaglutide is made with the drug in Wegovy but is not the same product, it was not studied in SELECT, and it has no FDA-approved labeling for cardiovascular risk reduction.